Prospects for targeted therapy of synovial sarcoma

Karen H. Albritton, R Randall

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Synovial sarcoma is a distinct tumor with unique promise for targeted therapy. It has a diagnostic translocation and a potentially informative fusion protein. It has moderate chemosensitivity, with about 50% response rates to regimens containing ifosfamide and doxorubicin. Therapeutic advances are unlikely to occur by continuing to lump synovial sarcomas in trials with other soft tissue sarcomas and adjusting traditional agents; rather, attention should be tumed toward prospective molecular targets and investigation or development of novel agents to exploit them. The SYT-SSX fusion protein that results from the X,18 translocation is an appealing target, as are the proteins overexpressed in synovial sarcoma: bcl-2, EGFR, and HER-2/neu.

Original languageEnglish (US)
Pages (from-to)219-222
Number of pages4
JournalJournal of Pediatric Hematology/Oncology
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2005
Externally publishedYes

Fingerprint

Synovial Sarcoma
Ifosfamide
Sarcoma
Doxorubicin
Proteins
Therapeutics
Neoplasms

Keywords

  • Synovial sarcoma
  • Targeted therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Prospects for targeted therapy of synovial sarcoma. / Albritton, Karen H.; Randall, R.

In: Journal of Pediatric Hematology/Oncology, Vol. 27, No. 4, 01.04.2005, p. 219-222.

Research output: Contribution to journalArticle

@article{527b7d704b5e40de8dd4cc4f88a91c83,
title = "Prospects for targeted therapy of synovial sarcoma",
abstract = "Synovial sarcoma is a distinct tumor with unique promise for targeted therapy. It has a diagnostic translocation and a potentially informative fusion protein. It has moderate chemosensitivity, with about 50{\%} response rates to regimens containing ifosfamide and doxorubicin. Therapeutic advances are unlikely to occur by continuing to lump synovial sarcomas in trials with other soft tissue sarcomas and adjusting traditional agents; rather, attention should be tumed toward prospective molecular targets and investigation or development of novel agents to exploit them. The SYT-SSX fusion protein that results from the X,18 translocation is an appealing target, as are the proteins overexpressed in synovial sarcoma: bcl-2, EGFR, and HER-2/neu.",
keywords = "Synovial sarcoma, Targeted therapy",
author = "Albritton, {Karen H.} and R Randall",
year = "2005",
month = "4",
day = "1",
doi = "10.1097/01.mph.0000163713.46762.72",
language = "English (US)",
volume = "27",
pages = "219--222",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Prospects for targeted therapy of synovial sarcoma

AU - Albritton, Karen H.

AU - Randall, R

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Synovial sarcoma is a distinct tumor with unique promise for targeted therapy. It has a diagnostic translocation and a potentially informative fusion protein. It has moderate chemosensitivity, with about 50% response rates to regimens containing ifosfamide and doxorubicin. Therapeutic advances are unlikely to occur by continuing to lump synovial sarcomas in trials with other soft tissue sarcomas and adjusting traditional agents; rather, attention should be tumed toward prospective molecular targets and investigation or development of novel agents to exploit them. The SYT-SSX fusion protein that results from the X,18 translocation is an appealing target, as are the proteins overexpressed in synovial sarcoma: bcl-2, EGFR, and HER-2/neu.

AB - Synovial sarcoma is a distinct tumor with unique promise for targeted therapy. It has a diagnostic translocation and a potentially informative fusion protein. It has moderate chemosensitivity, with about 50% response rates to regimens containing ifosfamide and doxorubicin. Therapeutic advances are unlikely to occur by continuing to lump synovial sarcomas in trials with other soft tissue sarcomas and adjusting traditional agents; rather, attention should be tumed toward prospective molecular targets and investigation or development of novel agents to exploit them. The SYT-SSX fusion protein that results from the X,18 translocation is an appealing target, as are the proteins overexpressed in synovial sarcoma: bcl-2, EGFR, and HER-2/neu.

KW - Synovial sarcoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=18044374788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044374788&partnerID=8YFLogxK

U2 - 10.1097/01.mph.0000163713.46762.72

DO - 10.1097/01.mph.0000163713.46762.72

M3 - Article

C2 - 15838395

AN - SCOPUS:18044374788

VL - 27

SP - 219

EP - 222

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -